Blog

CGTI Alireza Article Blog Post

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno- modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during biopreservation/stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe.…

Read More

BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million

Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.…

Read More
Iovance Blog Post

BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics

On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is…

Read More
TissueGene Blog Post

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions…

Read More

BioLife Solutions Executes Supply Agreement with Celyad

BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad,…

Read More
TissueGene Blog Post

BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis

Korean Approval Received by Kolon Life Science, TissueGene’s Exclusive Licensee BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media (“BioLife”), announced on July 13th 2017 that Kolon Life Science, TissueGene’s exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world’s…

Read More